# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-104915
**Filing Date:** 2025-11
**Character Count:** 9542
**Document Hash:** 642c877caba1229c0540fdb9a0b9f3cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-104915.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001213900-25-104915

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 251442174

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the<br> Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☒ <br> Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**INMED PHARMACEUTICALS INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

![](image_001.jpg)

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2025<br> ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON** <br> **DECEMBER 17, 2025**

Dear Shareholder:

You are receiving this notice because InMed Pharmaceuticals Inc. (the "**Company**") is using the notice-and-access rules for delivery of meeting materials for its 2025 Annual General and Special Meeting (the "**Meeting**") to its registered and beneficial shareholders. This notice regarding the Meeting is prepared pursuant to the notice-and-access rules under National Instrument 54-101 *– Communication with Beneficial Owners of Securities of a Reporting Issuer*, National Instrument 51-102 – *Continuous Disclosure Obligations* and pursuant to Rule 14a-16 under the United States Securities Exchange Act of 1934, as amended*.* Under notice-and-access, shareholders still receive a proxy or voting instruction form enabling them to vote at the Meeting. However, instead of a paper copy of the Notice of Meeting, Proxy Statement and Information Circular (the "**Proxy Statement**"), shareholders receive this notice with information on how they may access the Proxy Statement, 2025 Annual Report and form of proxy (collectively, the "**Meeting Materials**") electronically. The use of this alternative method of delivery is more environmentally responsible as it will reduce paper use and will also reduce the Company's printing and mailing costs. This notice is not a form for voting. You cannot use this notice to vote your shares. This notice presents only an overview of the more complete information in the Meeting Materials which contain important information and can be accessed online as provided below. Under United States Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the Meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the Meeting are also provided below.

The Company has elected not to use the procedure known as "stratification" in relation to its shareholders under the "notice and access" rules. Stratification occurs when a reporting issuer using the "notice and access" rules provides a paper copy of proxy-related materials to some, but not all, of its shareholders.

**The Meeting will be held in a virtual format on Wednesday, December 17, 2025 at 4:00 p.m. (PST). The Meeting will be conducted via telephone conference. You will not be able to attend the Meeting in person. Only shareholders who own common shares of the Company at the close of business on the record date of October 22, 2025 can submit their votes (not later than 4:00 p.m. (PST), on December 15, 2025, the proxy cut-off date for the meeting), or any adjournment or postponement of the Meeting.** 

To access the meeting by phone, please use the following conference call dial-in details:

---

| | |
|:---|:---|
| Canada - Toronto | +1.647.932.3411 |
| Canada - Toll-Free | +1.800.715.9871 |
| USA / International Toll | +1.646.307.1963 |
| USA - Toll-Free | +1.800.715.9871 |

---

The Meeting will begin promptly at 4:00 p.m. Pacific Standard Time. Access to the Meeting will open 15 minutes prior to the start of the Meeting.

**The purposes of the Meeting are:**

&nbsp;&nbsp;&nbsp;&nbsp;1. To receive the audited financial statements of the Company,
together with the auditors' report thereon, for the fiscal year ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;2. To elect the directors of the Company named in the Proxy
Statement to hold office until the next annual meeting of the Company or until their successors are duly elected. See "*Proposal 2: Election of Directors*" in the Proxy Statement.

&nbsp;&nbsp;&nbsp;&nbsp;3. To appoint CBIZ CPAs P.C. as the auditor/independent registered
public accounting firm for the Company for the ensuing year and to authorize the Directors to fix the auditors' remuneration. See
" *Proposal 3: Appointment of Auditor*" in the Proxy Statement.

&nbsp;&nbsp;&nbsp;&nbsp;4. To approve the potential issuance of 20% or more of the Company's
issued and outstanding common shares as of December 13, 2024 pursuant to the standby equity purchase agreement between the Company and
YA II PN, Ltd. dated December 13, 2024, as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b). See "*Proposal 4: SEPA Share Issuance Proposal* ".

&nbsp;&nbsp;&nbsp;&nbsp;5. To transact such further or other business as may properly
come before the Meeting or any adjournment(s) or postponement(s) thereof.

**MANAGEMENT AND THE BOARD RECOMMEND A VOTE FOR EACH NOMINEE AND FOR EACH MATTER TO BE VOTED ON.**

**This communication presents only an overview of the more complete proxy materials that are available to you on the internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.** 

You may access the proxy materials at www.inmedpharma.com, and at www.SEDARPlus.com. You may vote your shares online, by e-mail, by phone, by fax or by mail. Please refer to the directions on your voting instruction form or form of proxy for instructions on how to vote using these methods. To ensure that you have all the necessary information about the matters to be voted on at the Meeting, you should review the Proxy Statement before casting your vote.

For more information regarding notice-and-access or to obtain, at no charge, a paper or e-mail copy of the Meeting Materials you may contact our transfer agent, Odyssey Trust Company, via https://odysseytrust.com/ca-en/help/ or by phone at +1.888.290.1175 (toll-free within North America) or +1.587.885.0960 (direct from outside North America).

Requests may be made up to one year from the date the Proxy Statement was filed on SEDAR, but requests should be received at least five business days in advance of December 15, 2025, being the proxy cut-off date for voting at the Meeting, in order to receive the Meeting Materials in advance of the proxy cut-off date for the Meeting. If you do not request paper copies they will not otherwise be provided to you.

All shareholders of the Company are strongly encouraged to vote prior to the Meeting by any of the means described below.

**VOTING:** 

***Registered shareholders*** are asked to return their proxies using one of the following methods not later than 4:00 p.m. (PST), on December 15, 2025, being the proxy cut-off date for the Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;1. To
Vote Your Proxy Online please visit: https://vote.odysseytrust.com and click on LOGIN. You will require the CONTROL NUMBER printed
with your address to the right on your proxy form. If you vote by Internet, do not mail this proxy.

&nbsp;&nbsp;&nbsp;&nbsp;2. By mail or personal delivery to Odyssey Trust Company, Attn: Proxy Department, Suite 1100, 67 Yonge St., Toronto, Ontario, Canada M5E
1J8; or

&nbsp;&nbsp;&nbsp;&nbsp;3. By
fax to Odyssey, to the attention of the Proxy Department at 1-800-517-4553 (toll-free within Canada and the U.S.) or 416-263-9524 (international).

***Non-registered holders*** are asked to use the Voting Instruction Form provided by Broadridge, and RETURN IT TO BROADRIDGE (<u>not to the Company</u>), or vote through the Internet or by telephone as indicated on the Voting Instruction Form, in each case as soon as practicable to ensure that it is transmitted on time. It must be received by Odyssey or Broadridge, as applicable, with sufficient time for them to file a proxy by the proxy deadline of 4:00 p.m. (PST) on December 15, 2025.